FHLC:ARCA-Fidelity MSCI Health Care Index (USD)

ETF | Health | NYSE Arca

Last Closing

USD 65.41

Change

0.00 (0.00)%

Market Cap

USD 0.58B

Volume

0.19M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to provide investment returns that closely correspond to the price and yield performance of the Nasdaq Composite Index?. The fund normally invests at least 80% of assets in common stocks included in the index. It uses statistical sampling techniques that take into account such factors as capitalization, industry exposures, dividend yield, price/earnings (P/E) ratio, price/book (P/B) ratio, and earnings growth to create a portfolio of securities listed in the Nasdaq Composite Index that have a similar investment profile to the entire index.

Inception Date: 21/10/2013

Primary Benchmark: MSCI USA IMI/Health Care GR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.12%

Management Expense Ratio: 0.08 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV Health Care Select Sector SPDR.. 0.13 %

+0.75 (+0.54%)

USD 36.67B
FXH First Trust Health Care AlphaD.. 0.63 %

+0.16 (+0.15%)

USD 1.09B
BBH VanEck Biotech ETF 0.35 %

-0.25 (-0.16%)

USD 0.42B
XHE SPDR® S&P Health Care Equipme.. 0.35 %

-0.26 (-0.29%)

USD 0.21B
IDNA iShares Genomics Immunology an.. 0.00 %

+0.15 (+0.66%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF 0.50 %

-0.01 (-0.03%)

USD 0.11B
XHS SPDR® S&P Health Care Service.. 0.35 %

-0.09 (-0.10%)

USD 0.07B
HTEC Robo Global® Healthcare Techn.. 0.00 %

+0.09 (+0.29%)

USD 0.05B
BBP Virtus LifeSci Biotech Product.. 0.79 %

+0.23 (+0.38%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica.. 0.79 %

+0.16 (+0.64%)

USD 0.01B

ETFs Containing FHLC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.11% 24% F 43% F
Dividend Return 1.13% 63% D 18% F
Total Return 2.24% 38% F 33% F
Trailing 12 Months  
Capital Gain 2.06% 24% F 45% F
Dividend Return 1.14% 63% D 18% F
Total Return 3.20% 38% F 36% F
Trailing 5 Years  
Capital Gain 30.77% 76% C+ 66% D+
Dividend Return 8.20% 89% A- 24% F
Total Return 38.97% 86% B+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 8.70% 90% A- 62% D
Dividend Return 9.78% 90% A- 58% F
Total Return 1.08% 84% B 26% F
Risk Return Profile  
Volatility (Standard Deviation) 12.09% 95% A 75% C
Risk Adjusted Return 80.85% 90% A- 88% B+
Market Capitalization 0.58B 90% A- 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.